Promis Neurosciences Inc (TSE:PMN)’s share price dropped 5.3% on Friday . The stock traded as low as C$0.35 and last traded at C$0.36. Approximately 129,652 shares changed hands during trading, a decline of 55% from the average daily volume of 285,463 shares. The stock had previously closed at C$0.38.

Separately, Noble Financial reaffirmed a “buy” rating and set a C$1.00 price target on shares of Promis Neurosciences in a research note on Sunday, February 17th.

The company has a market capitalization of $94.86 million and a PE ratio of -10.57.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at

About Promis Neurosciences (TSE:PMN)

ProMIS Neurosciences, Inc, a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Its proprietary target discovery engine is based on the use of two complementary techniques.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with's FREE daily email newsletter.